Extended Evaluation of the Efficacy of a Proactive FOT-based Auto-CPAP Algorithm

NCT ID: NCT03070756

Last Updated: 2017-12-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-10-31

Study Completion Date

2018-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study implements an extended (post marked) examination of the efficacy of a proactive auto-CPAP algorithm, which is based on the forced oscillation technique (FOT) in a sample of patients with predominantly obstructive sleep apnea. The auto-CPAP algorithm examined in this study is implemented in the medical devices prisma20A and prismaLAB (Löwenstein Medical Technology).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients diagnosed with obstructive sleep apnea and who comply with inclusion criteria of the study will be informed about the possibility of participation. Following informed and written consent, participants will undergo a PSG-diagnostic night according to clinical routine, followed by an auto-CPAP treatment night with a prismaLINE device (prismaLAB or prisma20A). The device settings applied in the treatment night are defined by the study protocol (see interventions). Following the auto-CPAP treatment night, study participation is completed. Any following treatment and patient care is administered according to clinical routine.

Primary and secondary outcome measures of sleep stage and respiratory event indices are evaluated at diagnostic night and auto-CPAP treatment night.

The enrollment consists of two phases. During phase 1 (training phase) 10 participants are enrolled and complete the study protocol. Phase 1 serves as a training phase to establish a common standard of data quality and acquisition. Data of the training phase are not included in the statistical analysis. Following the training phase the efficacy of the auto-CPAP algorithm is evaluated in a sample of 70 participants.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obstructive Sleep Apnea

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

auto-CPAP forced oscillation technique obstructive sleep apnea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

treatment group (auto-CPAP)

Participants of this study undergo an diagnostic PSG night. The diagnostic night is followed by an auto-CPAP treatment night.

Interventions:

The treatment night is in line with the routine procedure of the laboratory except the following intervention: the device settings for the treatment night are applied according to the study protocol (minimal intervention).

Group Type OTHER

Minimal-Intervention - Specification of device settings

Intervention Type DEVICE

\- device settings for auto-CPAP treatment night: therapy mode=APAP, Pmin=5hPa,Pmax=20 hPa, Soft-Start duration \<=15 min, softPAP Level is selected based on patient comfort

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Minimal-Intervention - Specification of device settings

\- device settings for auto-CPAP treatment night: therapy mode=APAP, Pmin=5hPa,Pmax=20 hPa, Soft-Start duration \<=15 min, softPAP Level is selected based on patient comfort

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Specification of device settings

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Apnea-Hypopnea Index (AHI) \> 15,0 (n/h Total Sleep Time)
* Initial diagnosis of predominant obstructive sleep apnea (percentage of central respiratory events \< 20 %)
* informed written consent

Exclusion Criteria

* missing informed written consent
* Participation in another clinical trial that influences the initiation of auto-CPAP treatment by specifications of device settings or titration procedure
* acute cardiac decompensation
* severe arrhythmia
* severe hypotension, particularly in combination with intravascular volume depletion
* severe epistaxis
* high risk of barotrauma
* decompensated pulmonary conditions
* pneumothorax or pneumomediastinum
* pneumocephalus
* cranial trauma
* status following brain surgery or surgical intervention on the pituitary gland or the middle/inner ear
* acute sinus infection (sinusitis), middle ear infection (otitis media) or perforated eardrum
* dehydration


Data of patients who completed the study protocol will be excluded from statistical analysis if one of the following criteria applies:

* AHI \<= 15,0 (n/h TST) or percentage of central respiratory events \>= 20% in the second, study specific PSG-diagnostic night
* application of incorrect device settings
* insufficient data quality of PSG-acquisition
* the device was applied outside range of indication
* data of diagnostic night are not acquired as a PSG
* total time of softSTART duration exceeded 60 min
* the auto-CPAP device was restarted \>= 3 times during the treatment night. Recurrent reductions of device therapy pressure to start level (device restarts) which are applied within a time frame of \<= 5 minutes after another restart will be assigned to previous restart und therefore numbered as one. Restarts which take place before initial falling asleep will not be numbered.
* the application time of the auto-CPAP device was \<6h during treatment night
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Heinen und Löwenstein GmbH & Co. KG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Winfried J. Randerath, Professor

Role: STUDY_DIRECTOR

Wissenschaftliches Institut Bethanien e.V

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Wissenschaftliches Institut Bethanien e.V.

Solingen, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Regina Schäfer

Role: CONTACT

Phone: 004972182830

Email: [email protected]

Alexander Grimm

Role: CONTACT

Phone: 004972182830

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Winfried J. Randerath, Professor

Role: primary

Marcel Treml, PhD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

16-pLINE-AC-1

Identifier Type: -

Identifier Source: org_study_id